Evaluation of ruxolitinib, a JAK inhibitor, in multiple myeloma
A new research perspective titled "Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma" has been published in Oncotarget.
Feb 7, 2024
0
1